Non-Complement- and Complement-Activating Antibodies Synergize to Cause Rejection of Cardiac Allografts

American Journal of Transplantation

Volumn 4, Issue 3, 2004, Pages 326-334

  Rahimi, Salma ^a   Qian, Zhiping ^a   Layton, Jodi ^a   Fox Talbot, Karen ^a   Baldwin III, William M ^a   Wasowska, Barbara A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloantibodies; Cardiac transplant; Complement; Cytokines; IgKO

Indexed keywords

ALLOANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; VON WILLEBRAND FACTOR;

ACUTE GRAFT REJECTION; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GRAFT SURVIVAL; HEART GRAFT; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; INFLAMMATION; KNOCKOUT GENE; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE KC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT SYSTEM PROTEINS; DRUG SYNERGISM; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOGLOBULIN G; ISOANTIBODIES; MICE;

EID: 1442289511     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00334.x     Document Type: Article

References (64)

1. Mason DW, Morris PJ. Effector mechanisms in allograft rejection. Ann Rev Immunol 1986; 4: 119-145.
2. Feucht HE, Felber E, Gokel MJ et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
3. Burkhardt K, Weiss M, Riethmuller G et al, Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
4. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 1464-1475.
5. Saidman SL, Williams WW, Tolkoff-Rubin N et al, Complement activation in acute humoral renal allograft rejection; diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
6. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants, Springer seminars. Immunopathol 2003; 25: 119-140.
7. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
8. Feucht HE. Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3: 646-652.
9. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathological features of anti-class I-mediated rejection. Transplantation 1990; 49: 85-91.
10. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathological features of renal transplants with anti-class I-like antibody. Transplantation 1992;53:550-555.
11. Wasowska B, Baldwin WM III, Howell DN, Sanfilippo F. The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG antidonor class I alloantibody responses. Transplantation 1993; 56: 672-680.
12. Gracie JA, Bolton EM, Porteous C, Bradley JA. T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity. J Exp Med 1990; 172: 1547.
13. Bradley JA, Mowat AM, Bolton EM. Processed MHC class I alloantigen as the stimulus for CD4+ T-cell dependent antibody-mediated graft rejection. Immunol Today 1992; 13: 434-438.
14. Russell PS, Chase CM, Winn HJ, Colvin RB, Coronary atherosclerosis in transplanted mouse hearts II. Importance of humoral immunity. J Immunol 1994; 152: 5135-5141.
15. Kitamura D, Roes J, Kuhn R, Rajewsky KA, B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. Nature 1991; 350: 423-426.
16. Elwood ET, Ritchie SC, Aruffo A et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4-9.
17. Brandle D, Joergensen J, Zenke G, Burki K, Hof RP. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 1998; 65: 1489-1493.
18. Wesowska BA, Qian Z, Cangello DL et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001; 71: 727-736.
19. Wasowska BA, Qian Z, Behrens E, Cangello D, Sanfilippo F, Baldwin WM III. Inhibition of acute cardiac allograft rejection in immunoglobulin-deficient mice. Transplant Proc 1999; 31: 136.
20. Tran KV, Layton JL, Sanfilippo F et al. Alloantibodies restore cardiac allograft rejection to IgKO mice. Transplant Proc 2001; 33: 317.
21. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-C9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264: 9053-9060.
22. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985-992.
23. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807-1814.
24. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS, Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J. Immunol 1995; 155: 1434-1441.
25. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS, The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996; 149:953-961.
26. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates enclothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619-1627.
27. Rus HG, Niculescu FI, Shin M. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001; 180: 49-55.
28. Flory CM, Maheswari V, Tremontini NL et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997; 150: 2019-2031.
29. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in etherosclerotic lesion formation. Arterioscler Thromb Vasc. Biol 1996; 16: 673-677.
30. Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant 1995; 14: 151-162.
31. Leffell MS, King KE, Burdick JF et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-895.
32. Alejos JC, Burch C, Takemoto S et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22; 58-69.
33. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63: 1888-1893.
34. Bian H, Reed EF. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol 1999; 163:1010-1018.
35. Patterson GA, Cooper JD, Mohanakumar T, Anti HLAantibody binding to hla class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119: 39-45.
36. Millan MT, GeczyC, Stuhlmeier KM, Goodman DJ, Ferran C, Bach FH. Human monocytes activate porcine enclothelial cells, resulting in increased E-selectin, interleukin-8, monocyte chemotactic protein-1, and plasminogen activator inhibitor-type-1 expression. Transplantation 1997; 63: 421-429.
37. Vos IH, Briscoe DM, Endothelial injury; cause and effect of alloimmune inflammation. Transpl Infect Dis 2002; 4: 152-159.
38. Pidwell DJ, Heller MJ, Gabler D, Orosz CG, In vitro stimulation of human endothelial cells by sera from a subpopulation of high-percentage panel-reactive antibody patients. Transplantation 1995;60;563-569.
39. Galfayan K, Galera O, Trento A et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67: 385-391.
40. Harris PE, Bian H, Reed EF. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 1997: 159: 5697-5704.
41. Abdullah N, Greenman J, Pimendiou A, Topping KP, Monson JR. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumor cells. Can Immunol. Immunother 1999; 48: 517-524.
42. Macdermott RP, Nash GS, Merkle NS, Weinrieb IJ, Bertovich MJ, Formeister JF. Further evidence that antibody-dependent and spontaneous cell-mediated cytotoxicity are mediated by different processes or cell types. Immunology 1980; 41: 439-447.
43. Miltenburg AMM, Meijer-Paape ME, Weening JJ, Daha MR, van Es LA, van der Woude FJ. Induction of antibody-dependent cellular cytotoxicity against endothelial cells by renal transplantation. Transplantation 1989; 48: 681.
44. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14: 215-221.
45. Altman PL, Katz DD. Inbred and Genetically Defined Strains of Laboratory Animals. Bethesda: FASEB, 1979.
46. Sechler JM, Yip JC, Rosenberg AS. Genetic variation among 129 substrains: practical consequences. J Immunol 1997; 159: 5766-5768.
47. Burdick JF, Clow LW. Rejection of murine cardiac allografts. I. Relative roles of major and minor antigens. Transplantation 1986; 42: 67-72.
48. O'Connell KA, Edidin M. A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol 1990; 144: 521-525.
49. Ozato K, Mayer N, Sachs DH. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J Immunol 1980; 124:533-540.
50. Ollert MW, Kadlec JV, David K, Petrella EC, Bredehorst R, Vogel CW. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 1994; 153: 2213-2221.
51. Exner M, Regele H, Dancea S et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative antihuman globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807-2814.
52. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Kopchaliiska D, Leffell MS. Specific and durable elimination of antibody to donor HLA antigens in renal transplant patients. Am J Transplant 2004, in press.
53. Suzuki T. Signal transduction mechanisms through Fc gamma receptors on the mouse macrophage surface. FASEB J 1991; 5: 187-193.
54. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Ann Rev Immunol 1998; 16: 421-432.
55. Qian Z, Jakobs FM, Pfaff-Amesse T, Sanfilippo F, Baldwin WM III, Complement contributes to the rejection of complete and Class I MHC incompatible cardiac allografts. J Heart Lung Transplant 1998; 17: 470-478.
56. Nakashima S, Qian Z, Rahimi S, Wasowska BA, Baldwin WM III. Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol 2002; 169: 4620-4627.
57. Selvan RS, Kapadia HB, Platt JL, Complement-induced expression of chemokine genes in endothelium: regulation by IL-1-dependent and -independent mechanisms. J Immunol 1998; 161: 4388-4395.
58. Saadi S, Holzknecht RA, Patte CP, Platt JL. Endothelial cell activa activation by pore-forming structures: pivotal role for interleukin-1 alpha. Circulation 2000; 101: 1867-1873.
59. Ey PL, Prowse SJ, Jenkin CR. Complement-fixing IgG1 constitutes a new subclass of mouse IgG. Nature 1979; 281: 492-493.
60. Ey PL, Russell-Jones GJ, Jenkin CR. Isotypes of mouse IgGI. Evidence for 'non-complement-fixing IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement. Mol Immunol 1980; 17: 699-710.
61. Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981; 11: 1012-1016.
62. White KD, Frank MB, Foundling S, Waxman FJ. Effect of immunoglobulin variable region structure on C3b and C4b deposition. Mol Immunol 1996; 33: 759-768.
63. Yokoyama I, Waxman F. Differential susceptibility of immune complexes to release from the erythrocyte CR1 receptor by factor I. Mol Immunol 1994; 31: 227-240.
64. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988; 18:1507-1514.